Powered by OpenAIRE graph
Found an issue? Give us feedback
ZENODOarrow_drop_down
ZENODO
Report . 2024
License: CC BY
Data sources: Datacite
ZENODO
Report . 2024
License: CC BY
Data sources: Datacite
versions View all 2 versions
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

UNLOCKING HOPE: THE PROMISE OF IVACAFTOR, LUMACAFTOR, THEIR COMBINATION IN CYSTIC FIBROSIS TREATMENT AND GENE THERAPY

Authors: Poojitha Modepalli, Ramesh Chinnabala, Om Vinay Dappu, Ramarao Tadikonda, Gayatri Devi Yasa*;

UNLOCKING HOPE: THE PROMISE OF IVACAFTOR, LUMACAFTOR, THEIR COMBINATION IN CYSTIC FIBROSIS TREATMENT AND GENE THERAPY

Abstract

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. A protein that controls the flow of salt into and out of cells are altered in cystic fibrosis due to a flaw (mutation) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As a result, sweat becomes more salted and the respiratory, digestive, and reproductive systems produce thick, sticky mucus. A novel medicinal drug called ivacaftor modifies the function of the CFTR channel. For patients who are homozygous for the F508del mutation in the CFTR gene, lumacaftor is a protein chaperone that is used in conjunction with ivacaftor to treat cystic fibrosis. Lumacaftor-ivacaftor is indicated for treatment of CF in patients homozygous for the Phe-508del CFTR gene mutations. Without the treatment and perfect knowledge on the disease leads to death of the patient on suffering with CF. A significant step in the development of CF gene therapy was the cloning of the CFTR gene. This review mainly describes about the cystic fibrosis and its treatment ways and procedures. The drugs like ivacaftor, lumacaftor, different combinations of drugs and also discussed about the gene therapy and agents of gene therapy for cystic fibrosis. Key words: Cystic fibrosis, ivacaftor, lumacaftor, gene therapy.

  • BIP!
    Impact byBIP!
    citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
citations
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green
Related to Research communities
Upload OA version
Are you the author of this publication? Upload your Open Access version to Zenodo!
It’s fast and easy, just two clicks!